A systematic review of economic evaluations of vaccines in Middle East and North Africa countries: is existing evidence good enough to support policy decision-making?

References

• Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• Greenwood B. The contribution of vaccination to global health: past, present and future. Philosophical transactions of the Royal Society of London. Series B, Biol Sci. 2014;369(1645):20130433.
   Google Scholar
• World Health Organization. Vaccine and Immunization. (Ed.^(Eds). 2019. Availble from: https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1
   Google Scholar
• Jauregui B, Garcia AG, Bess Janusz C, et al. Evidence-based decision-making for vaccine introductions: overview of the ProVac International Working Group’s experience. Vaccine. 2015;33(Suppl 1):A28–33.
   PubMedGoogle Scholar
• Abed GT, Davoodi HR Challenges of growth and globalization in the Middle East and North Africa. (Ed.^(Eds) (nternational Monetary Fund, 2003)
   Google Scholar
• Asbu EZ, Masri MD, Kaissi A. Health status and health systems financing in the MENA region: roadmap to universal health coverage. Glob Health Res Policy. 2017;2(1). DOI:https://doi.org/10.1186/s41256-017-0044-9
   Google Scholar
• Kaddar M, Saxenian H, Senouci K, et al. Vaccine procurement in the Middle East and North Africa region: challenges and ways of improving program efficiency and fiscal space. Vaccine. 2019;37(27):3520–3528.
   PubMed Web of Science ®Google Scholar
• UNICEF.Immunization Financing in MENA Middle-Income Countries. (Ed.^(Eds) (May 2018)
   Google Scholar
• WHO. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring. Geneva: World Health Organization; 2014.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programme. Third edition. Oxford: Oxford University Press; 2005.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Wong CKH, Liao Q, Guo VYW, et al. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: a systematic review. Vaccine. 2017;35(24):3153–3161.
   PubMed Web of Science ®Google Scholar
• Akin L, Kaya M, Altinel S, et al. Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination in at risk adults and elderly in Turkey. Hum Vaccines. 2011;7(4):441–450.
   PubMedGoogle Scholar
• Akin L, Macabeo B, Caliskan Z, et al. Cost-effectiveness of increasing influenza vaccination coverage in adults with type 2 diabetes in Turkey. PloS One. 2016;11(6):e0157657.
   PubMed Web of Science ®Google Scholar
• Al Awaidy ST, Gebremeskel BG, Al Obeidani I, et al. Cost effectiveness of a pentavalent rotavirus vaccine in Oman. BMC Infect Dis. 2014;14(1). DOI:https://doi.org/10.1186/1471-2334-14-334
   Google Scholar
• AYA A-A, Standaert B, Meszaros K, et al. Economic assessment of rotavirus vaccination in Saudi Arabia. J Infect Public Health. 2017;10(5):564–571.
   PubMed Web of Science ®Google Scholar
• Alkoshi S, Maimaiti N, Dahlui M. Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model. Libyan J Med. 2014;9(1):26236.
   Google Scholar
• Anwari P, Debellut F, Pecenka C, et al. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan. Vaccine. 2018;36(51):7769–7774.
   PubMed Web of Science ®Google Scholar
• Bahr S, Bzieh R, El Hayek GY, et al. Cost–benefit analysis of a projected national human papilloma virus vaccination programme in Lebanon. East Mediterr Health J. 2019;25(10):715–721.
   PubMed Web of Science ®Google Scholar
• Bakir M, Turel O, Topachevskyi O. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model. BMC Health Serv Res. 2012;12(386). DOI:https://doi.org/10.1186/1472-6963-12-386
   Google Scholar
• Bakir M, Standaert B, Turel O, et al. Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Vaccine. 2013;31(6):979–986.
   PubMed Web of Science ®Google Scholar
• Chodick G, Ashkenazi S, Livni G, et al. Cost-effectiveness of varicella vaccination of healthcare workers. Vaccine. 2005;23(43):5064–5072.
   PubMed Web of Science ®Google Scholar
• Chodick G, Lerman Y, Wood F, et al. Cost-utility analysis of hepatitis A prevention among health-care workers in Israel. J Occup Environ Med. 2002;44(2):109–115.
   PubMed Web of Science ®Google Scholar
• Chodick G, Waisbourd-Zinman O, Shalev V, et al. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel. Eur J Public Health. 2009;19(3):254–259.
   PubMed Web of Science ®Google Scholar
• Esmaeeli S, Yaghoubi M, Nojomi M. Cost-effectiveness of varicella vaccination program in Iran. Int J Prev Med. 2017 Dec 5;8:103. DOI:https://doi.org/10.4103/ijpvm.IJPVM_295_16.
   Google Scholar
• Ezoji K, Yaghoubi M, Nojomi M, et al. Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the islamic republic of Iran. East Mediterr Health J. 2019;25(10):686–697.
   PubMed Web of Science ®Google Scholar
• Gamaoun R. National cervical cancer prevention program in the Arab States: strategies and cost-minimization study of the Tunisian case. Vaccine. 2018;36(33):5091–5096.
   PubMed Web of Science ®Google Scholar
• Gargano LM, Tate JE, Parashar UD, et al. Comparison of impact and cost-effectiveness of rotavirus supplementary and routine immunization in a complex humanitarian emergency, Somali case study. Confl Health. 2015;9:5. DOI: https://doi.org/10.1186/s13031-015-0032-y.
   Google Scholar
• Gargano LM, Hajjeh R, Cookson ST. Pneumonia prevention during a humanitarian emergency: cost-effectiveness of haemophilus influenzae type B conjugate vaccine and pneumococcal conjugate vaccine in Somalia. Prehosp Disaster Med. 2015;30(4):402–411.
   PubMed Web of Science ®Google Scholar
• Gillis D, Yetiv N, Gdalevich M, et al. Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis. Vaccine. 2000;18(26):3005–3010.
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Kassis I, Dagan R. Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel. J Epidemiol Community Health. 1993;47(6):485–490.
   PubMed Web of Science ®Google Scholar
• Ginsber GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol. 2001;34(1):92–99.
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Berger S, Shouval D. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity. Bull World Health Organ. 1992;70(6):757–767.
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Community Health. 1992;46(6):587–594.
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Block C, Stein-Zamir C. Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel. Int J Public Health. 2016;61(6):683–692.
   PubMed Web of Science ®Google Scholar
• Ginsberg GM. Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel. Vaccine. 2013;31(Suppl 8):I46–52.
   PubMedGoogle Scholar
• Ginsberg GM, Fisher M, Ben-Shahar I, et al. Cost-utility analysis of vaccination against HPV in Israel. Vaccine. 2007;25(37–38):6677–6691.
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Somekh E, Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - A cost-utility analysis. Isr J Health Policy Res. 2018;7(1). DOI:https://doi.org/10.1186/s13584-018-0258-4
   Google Scholar
• Hacimustafaoǧlu M, Çelebi S, Akin L, et al. Cost effectiveness of both (Monovalent and Pentavalent) rotavirus vaccines. Cocuk Enfeksiyon Dergisi. 2013;7(1):13–20.
   Google Scholar
• Hayajneh WA, Daniels VJ, James CK, et al. Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach. BMC Infect Dis. 2018;18(1):119.
   PubMedGoogle Scholar
• Javanbakht M, Moradi-Lakeh M, Yaghoubi M, et al. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran. Vaccine. 2015;33(Suppl 1):A192–200.
   PubMedGoogle Scholar
• Khatibi M, Rasekh HR, Shahverdi Z, et al. Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran. Iran J Pharm Res. 2014;13(SUPPL):225–234.
   PubMedGoogle Scholar
• Kim JJ, Sharma M, O’Shea M, et al. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA). Vaccine. 2013;31(Suppl 6):G65–77.
   PubMedGoogle Scholar
• Koksal T, Akelma AZ, Koksal AO, et al. Cost-effectiveness of rotavirus vaccination in Turkey. J Microbiol Immunol Infect. 2017;50(5):693–699.
   PubMedGoogle Scholar
• Mansour-Ghanaei R, Moradi-Lakeh M, Karimi A, et al. Future strategic plan for national immunisation program in Iran: cost effectiveness of acellular pertussis versus whole-cell. Int J Foresight Innovation Policy. 2018;13(1–2):136–147.
   Google Scholar
• Marijam A, Olbrecht J, Ozakay A, et al. Comparison of Pneumococcal Conjugate Vaccines in Turkish Children. Value Health Reg Issues. 2019;19(34):34–44.
   PubMedGoogle Scholar
• Messoudi W, Elmahi T, Nejjari C, et al. Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. J Med Econ. 2019;22(11):1153–1159.
   PubMedGoogle Scholar
• Moradi-Lakeh M, Shakerian S, Esteghamati A. Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses. Int J Prev Med. 2012;3(5):332–340.
   PubMedGoogle Scholar
• Mousavi Jarrahi Y, Zahraei SM, Sadigh N, et al. The cost effectiveness of rotavirus vaccination in Iran. Hum Vaccin Immunother. 2016;12(3):794–800.
   PubMed Web of Science ®Google Scholar
• Ortega O, El-Sayed N, Sanders JW, et al. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis. 2009;200(SUPPL. 1):S92–S98.
   PubMedGoogle Scholar
• Patel HD, Roberts ET, Constenla DO. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Vaccine. 2013;31(51):6072–6078.
   PubMed Web of Science ®Google Scholar
• Pugh SJ, Fletcher MA, Charos A, et al. Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria. Infect Dis Ther. 2019;8(1):63–74.
   PubMed Web of Science ®Google Scholar
• Rheingans R, JDt A, Bagamian KH, et al. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan. Vaccine. 2018;36(51):7780–7789.
   PubMed Web of Science ®Google Scholar
• Shakerian S, Lakeh MM, Esteghamati A, et al. Cost-effectiveness of rotavirus vaccination for under-five children in Iran. Iran J Pediatr. 2015;25(4). DOI:https://doi.org/10.5812/ijp.2766
   Google Scholar
• Sibak M, Moussa I, El-Tantawy N, et al. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. Vaccine. 2015;33(Suppl 1):A182–191.
   PubMedGoogle Scholar
• Turel O, Kisa A, McIntosh ED, et al. Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey. Value Health. 2013;16(5):755–759.
   PubMed Web of Science ®Google Scholar
• Yaghoubi M, Nojomi M, Vaezi A, et al. Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran. Value Health Reg Issues. 2018;15(112):112–119.
   PubMedGoogle Scholar
• Yamin D, Balicer RD, Galvani AP. Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel. Vaccine. 2014;32(33):4198–4205.
   PubMed Web of Science ®Google Scholar
• WHO. Macroeconomics and health. Investing in health for economic development. Executive summary/report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
   Google Scholar
• van der Putten IM, Evers SM, Deogaonkar R, et al. Stakeholders’ perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study. BMC Public Health. 2015;15(356). DOI:https://doi.org/10.1186/s12889-015-1638-0
   Google Scholar
• Chit A, Lee JKH, Shim M, et al. Economic evaluation of vaccines in Canada: a systematic review. Hum Vaccin Immunother. 2016;12(5):1257–1264.
   PubMed Web of Science ®Google Scholar
• Sartori AMC, Rozman LM, Decimoni TC, et al. A systematic review of health economic evaluations of vaccines in Brazil. Hum Vaccin Immunother. 2017;13(6):1–12.
   PubMed Web of Science ®Google Scholar
• Prinja S, Singh Chauhan A, Angell B, et al. Review of the State of Economic Evaluation for Health Care in India. Appl Health Econ Health Policy. 2015;13(6):595–613.
   PubMed Web of Science ®Google Scholar
• Pan XF, Griffiths UK, Pennington M, et al. Systematic review of economic evaluations of vaccination programs in mainland China: are they sufficient to inform decision making? Vaccine. 2015;33(46):6164–6172.
   PubMed Web of Science ®Google Scholar
• Fasseeh A, Karam R, Jameleddine M, et al. Implementation of health technology assessment in the middle east and north africa: comparison between the current and preferred status. Front Pharmacol. 2020; 11:15. DOI:https://doi.org/10.3389/fphar.2020.00015.
   Google Scholar
• Alefan Q, Hamdouni E, Alhamad H, et al. Barriers to implementing pharmacoeconomics: interview study. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):93–104.
   PubMed Web of Science ®Google Scholar
• Mohtasham F, Yazdizadeh B, Zali Z, et al. Health technology assessment in Iran: barriers and solutions. Med J Islam Repub Iran. 2016;30:321.
   Google Scholar
• WHO. Eastern Mediterranean vaccine action plan 2016–2020: a framework for implementation of the global vaccine action plan. Cairo: WHO Regional Office for the Eastern Mediterranean; 2019. Licence: CC BY-NC-SA 3.0 IGO. (Ed.^(Eds) (2019)
   Google Scholar
• Obeid DA, Almatrrouk SA, Alfageeh MB, et al. Human papillomavirus epidemiology in populations with normal or abnormal cervical cytology or cervical cancer in the Middle East and North Africa: a systematic review and meta-analysis. J Infect Public Health. 2020;13(9):1304–1313.
   PubMed Web of Science ®Google Scholar
• Office WroftEM. COVAX Facility allocating additional COVID-19 vaccines as countries push vaccination drives. (Ed.^(Eds) (2021)
   Google Scholar
• Hagens A, AÇ İ, Yildirak K, et al. COVID-19 Vaccination Scenarios: a cost-effectiveness analysis for Turkey. Vaccines (Basel). 2021;9(4):399.
   PubMed Web of Science ®Google Scholar
• Kohli M, Maschio M, Becker D, et al. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021;39(7):1157–1164.
   PubMed Web of Science ®Google Scholar
• Sandmann FG, Davies NG, Vassall A, et al. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis. 2021;S1473-3099(21):7–79.
   Google Scholar
• Cassimos DC, Effraimidou E, Medic S, et al. Vaccination Programs for Adults in Europe, 2019. Vaccines (Basel). 2020;8(1):34.
   PubMed Web of Science ®Google Scholar
• Bell S, Blanchard L, Walls H, et al. Value and effectiveness of National Immunization Technical Advisory Groups in low- and middle-income countries: a qualitative study of global and national perspectives. Health Policy Pla. 2019 34(271–281).
   PubMedGoogle Scholar
• Greene SA, Anya BM, Asghar H, et al. Strengthening national immunization technical advisory groups in resource-limited settings: current and potential linkages with polio national certification committees. Health Res Policy Syst. 2020;18:116. DOI: https://doi.org/10.1186/s12961-020-00632-7.
   Google Scholar
• Gandjour A. Considering productivity loss in cost-effectiveness analysis: a new approach. Eur J Health Econ. 2014;15(8):787–790.
   PubMed Web of Science ®Google Scholar
• Johannesson M. Avoiding Double-Counting in Pharmacoeconomic Studies. PharmacoEconomics. 1997;11(5):385–388.
   PubMed Web of Science ®Google Scholar
• Weinstein MC. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(15):1253–1258.
   PubMed Web of Science ®Google Scholar
• Leech AA, Kim DD, Cohen JT, et al. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: trends in Cost-per-DALY Studies. Value Health. 2018;21(7):759–761.
   PubMed Web of Science ®Google Scholar
• Robinson LA, Hammitt JK, Chang AY, et al. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2016;32(1):141–145.
   PubMed Web of Science ®Google Scholar
• Woods B, Revill P, Sculpher M, et al. Thresholds: initial Estimates and the Need for Further Research. Value Health. 2016;19(8):929–935.
   PubMed Web of Science ®Google Scholar
• Smith KM, Machalaba CC, Seifman R, et al. Infectious disease and economics: the case for considering multi-sectoral impacts. One Health. 2019;7(100080):100080.
   PubMedGoogle Scholar
• Al-Aqeel S. Health technology assessment in Saudi Arabia. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):393–402.
   PubMed Web of Science ®Google Scholar
• GAVI. Eligibility for Gavi support is determined by countries’ national income. (Ed.^(Eds) (2021)
   Google Scholar
• Saxenian H, Sadr-Azodi N, Kaddar M, et al. Immunisation financing and programme performance in the Middle East and North Africa, 2010 to 2017. BMJ Glob Health. 2019;4(2):e001248.
   PubMed Web of Science ®Google Scholar
• Khoja T, Rawaf S, Qidwai W, et al. Health Care in Gulf Cooperation Council Countries: a Review of Challenges and Opportunities. Cureus. 2017;9(8):e1586–e1586.
   PubMed Web of Science ®Google Scholar